oturkibart (QX005N) / Qyuns Therap, Huadong Medicine - LARVOL DELTA

Efficacy and Safety of Oturkibart in Adults with Prurigo Nodularis: 52-Week Results from a Phase 3 Trial (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Immunology • Prurigo Nodularis

Efficacy and Safety of QX005N in Adults with Prurigo Nodularis: Results from a multicenter, randomized, double-blinded, placebo-controlled phase 3 trial (EADV 2026) - No abstract available

Clinical • P3 data • Immunology • Prurigo Nodularis

A randomized, open, parallel phase I trial to Investigate the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of QX029N Injection and to compare the pharmacokinetic characteristics of QX029N Injection with QX005N Injection in healthy subjects (ChiCTR) - P1 | N=152 | Not yet recruiting | Sponsor: Hangzhou First People's Hospital; Hangzhou First People's Hospital

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

COMPLETION OF SUBJECT ENROLLMENT FOR QX005N PHASE III CLINICAL TRIAL FOR THE TREATMENT OF PRURIGO NODULARIS (HKEXnews) - "The Company is pleased to announce that on March 19, 2025, a total of 409 subjects were enrolled for the Phase III clinical trial of QX005N, an injection for PN independently discovered and developed by the Company (registration number: CTR20241660). This is the first Phase III clinical trial conducted by a Chinese domestic enterprise for the indication of PN in China, and is currently the world’s largest pivotal clinical trial of PN in terms of subject size....This is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of QX005N in adult subjects with PN."

Enrollment closed • Prurigo Nodularis